After publication of the results of the European Society of Cataract and Refractive Surgery (ESCRS) study, there is a lot of enthusiasm for using intracameral antibiotics for the prevention of postcataract endophthalmitis. However, despite level 1 evidence, the practice has not been adopted universally. The aim of this review is to present a summary of the articles published in the last 18 months on this topic.
The published literature highlights that the incidence rate of endophthalmitis declined after 2007. Simultaneously, there is a rising trend for using intracameral injection of antibiotics at the conclusion of cataract surgery. Although various drugs have been used for this purpose, nearly all provide comparable protection. Industry has started manufacturing formulations for commercial availability of intracameral injection. Innovations are also ongoing to use intraocular lens for drug delivery and developing other intraocular drug delivery devices.
Endophthalmitis prevention is at an interesting crossroad. Although there is hesitation the intracameral injection of antibiotics is increasingly being adopted by physicians, which is likely to grow further with commercial availability of formulations. However, it will be important to be cautious and report all adverse reactions associated with this practice.
aTej Kohli Cornea Institute, KAR Campus, L. V. Prasad Eye Institute, Hyderabad
bTej Kohli Cornea Institute, KVC Campus, L. V. Prasad Eye Institute, Vijayawada
cJhaveri Microbiology Centre, KAR Campus, L. V. Prasad Eye Institute, Hyderabad, India
Correspondence to Dr Prashant Garg, MBBS, MS, L. V. Prasad Eye Institute, L. V. Prasad Marg, Banjara Hills, Hyderabad 500034, India. Tel: +91 40 30612345; fax: +91 40 23548271; e-mail: email@example.com